Profile of candidiasis in HIV infected patients
,
Abstract
Background and Objective: Candidiasis is a common opportunistic infection in HIV-infected patients. The spectrum of Candida infection is diverse, starting from asymptomatic colonization to pathogenicforms. The low absolute CD4+ T-lymphocyte count has traditionally been cited as the greatest risk factor for the development of Oropharyngeal Candidiasis and current guidelines suggest increased risk once CD4+ T lymphocyte counts fall below 200 cells/μL. Gradual emergence of non-albicans Candida species as a cause of refractory mucosal and invasive Candidiasis, particularly in patients with advanced immunosuppression and problem of resistance to azoles and other antifungal agents in the Candida species is a point of concern.
Materials and Methods: A prospective study was carried out over a period of 2 years (2010-2011) on patients suffering from AIDS for the presence of Candida infection. After thorough clinical examination relevant specimens were collected and processed specifically to ascertain Candida infection. Speciation of Candida isolates and antifungal sensitivity testing was also done. The CD4 cell counts of all the patients were estimated and correlated with the presence (or absence) of candidiasis.
Results: Out of a total of 165 HIV positive patients, a definitive diagnosis of candidiasis was made in 80 patients. Candida albicans was the most common yeast isolated. Patients with candidiasis had CD4 counts less than 200 cells/mm3. Maximum resistance was seen with fluconazole while no resistance was seen with voriconazole.
Conclusion: The most common opportunistic fungal infection in HIV positive patients is candidiasis, affecting the mucocu- taneous system mainly but the invasive form is also common. Resistance to azoles and other antifungal agents in the Candida species is a point of concern.
Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of the virus in plasma. Science 1996; 272:1167-1170.
Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C. et al. Randomisedplacebo- controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease RitonavirStudy Group. Lancet 1998; 351(9102): 543-549.
Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, Souala F, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1815-1822.
Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7:429-439.
Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12(4): 447-8.
Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12(18): 2511-3.
U.S. Public Health Service, Infectious Diseases Society of American Guidelines for preventing opportunistic infections among HIV-infected persons-2002. MMWR Recomm Rep. 2002 Jun 14; 51(RR08).
Calderone RA. Candida and candidiasis. Washington, DC: ASM Press, 2001.
Armstrong, D. 1989. Problems in management of opportunistic fungaldiseases. Rev. Infect. Dis. 1 l (Supp1. 7): S1591-S1599.
Barr CE. Oral diseases in HIV-1 infection.Dysphagia.1992;7: 126-37.
Chander J. Candidiasis. Textbook of Medical Mycology,2nd ed. New Delhi:Mehta Publishers; 2009. p. 266-90.
Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. Sep 12003;37(5): 634-43.
M. Vajpayee, S. Kanswal, P. Seth, N. Wig. Spectrum of Opportunistic Infections and Profile of CD4+ Counts among AIDS Patients in North India Infection 2003; 31:336-340.
Sharma SK, Aggarwal G, Seth P, Saha PK: Increasing HIV seropositivity among adult tuberculosis patients in Delhi. Indian J MedRes 2003, 117: 239-242.
Anupriyawadhwa, Ravinder Kaur, Satish Kumar Agarwal, Shyama Jain and PreenaBhalla: AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India; Journal of Medical Microbiology 2007; 56:1101-1106.
B.C. Pruthvi, S. Vikram, S.K. Suman, B. Jayaprakash, N.R.Rau, Spectrum of Clinical Presentation and Opportunistic Infections in HIV: An Indian Scenario,13th International Congress on Infectious Diseases, e484,2006.
Nagalingeswaran K, Solomon S,Madhivanan P, Yepthomi T, Venkatesan C, Amalraj E et al. Correlation between plasma viral load and CD4+T cell count to opportunistic infections in persons with HIV in South India. Int Conf AIDS. 2000 Jul 9-14; 13.
Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci 2003; 57: 16-21.
Sanjeypandey, Shyam Sunder, H Hasan, Ravi Shankar, SP Singh. Clinical profile and opportunistic infections in HIV/AIDS patients attending SS hospital varanasi, Indian J PrevSoc Medicine, vol. 39 no. 1 & 2, 2008.
Mulla SA, Patel MG, Vaghela G, Motala N, Desai V, Shrivastava RK. A study of opportunistic infection in HIVseropositive patients. Indian J Community Med 2007; 32: 208-9.
Ismail H. Sahand, Jose L. Maza, Elena Eraso, Miguel Montejo, Marı´a D. Moragues, Jose M. Aguirr et al. Evaluation of CHROM-Pal medium for the isolation and direct identification of Candida dubliniensis in primary cultures from the oral cavity. Journal of Medical Microbiology (2009), 58, 1437-1442.
Coleman, DC et al.Candidiasis: The emergence of a novel species,Candida dubliniensis. AIDS. 1997;11557-567.
CA Enwuru1, A Ogunledun, N Idika, NV Enwuru, F Ogbonna, M. Aniedobeet al. Fluconazole resistant opportunistic oropharyngeal candida and non-candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. African Health Sciences.2008; 8 No 3.
Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates fromhuman immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997; 41(3): 617-623.
Vazquez JA, Arganoza MT, Boikov D, Yoon S,Sobel JD, Akins RA. Stable phenotypic resistance of Candidaspecies to amphotericin B conferred by pre-exposuretosub-inhibitory levels of azoles. J Clin Microbiol 1998; 36(9): 2690-2695.
Cartledge JD, Midgely J, Gazzard BG. Clinically significantazole cross-resistance in Candida isolates from HIVpositivepatients with oral candidosis. AIDS 1997; 11: 1839-1844.
Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-6.
| Files | ||
| Issue | Vol 4 No 4 (2012) | |
| Section | Articles | |
| Keywords | ||
| AIDS CD4 count Candida HIV | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
